Patients meeting the primary outcome gained 14.5 more good days with eptinezumab, while others gained 1.7 days. An improvement of at least 75% in self-rated good days per month serves as a ...
Investigational Lu AG09222 bested placebo in preventing migraine in a phase II trial. The treatment showed a 2-day difference in reducing monthly migraine days. Lu AG09222 targets PACAP, a ...
Hosted on MSN
Rimegepant reduces migraine days in difficult cases
Two Phase 4 trials published in Cephalalgia found that rimegepant significantly reduced monthly migraine days in patients who had failed multiple preventive treatments. The oral CGRP receptor ...
If you've ever had to draw the curtains, silence your phone and crawl into bed because a migraine has taken over your day, you know this isn't "just a headache." Migraines can steal hours, derail ...
3d
Lahey Hospital utilizes minimally invasive treatment to change chronic migraine care for local girl
This novel treatment bridges traditional neurology and neurointerventional surgery, offering a specialized alternative for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results